DRUG COMPANY SPONSORSHIP AFFECTS ECONOMIC ASSESSMENT OF
ONCOLOGY DRUGS In economic analyses of breakthrough oncology drugs,
disclosure of unfavorable results is significantly less likely when the
research was funded by a pharmaceutical company than when a nonprofit
organization sponsored the study. http://oncology.medscape.com/13160.rhtml <a
href="http://oncology.medscape.com/13160.rhtml">Read it
Here</a>